Table 2.
Outcomes in the whole and matched cohorts.
| Whole cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
| SCS (n = 269) |
HOPE (n = 25) |
p* | SCS (n = 50) |
HOPE (n = 25) | p* | |
| Stage 2–3 acute kidney injury | 87 (32.3%) | 4 (16.0%) | 0.14 | 21 (42.0%) | 4 (16.0%) | 0.046 |
| Dialysis post-LT | 8 (3.0%) | 1 (4.0%) | 1.00 | 2 (4.0%) | 1 (4.0%) | 1.00 |
| Severe post-reperfusion syndrome | 42 (15.6%) | 1 (4.0%) | 0.20 | 10 (20.0%) | 1 (4.0%) | 0.13 |
| Early allograft dysfunction | 86 (32.0%) | 8 (32.0%) | 1.00 | 17 (34.0%) | 8 (32.0%) | 1.00 |
| ALT peak (IU/L) | 973 (889) | 792 (773) | 0.32 | 817 (540) | 792 (773) | 0.87 |
| AST peak (IU/L) | 1560 (1238) | 1425 (1729) | 0.62 | 1498 (1034) | 1425 (1729) | 0.82 |
| Lactate at the end of LT | 2.43 (1.49) | 2.46 (1.24) | 0.91 | 2.75 (2.22%) | 2.46 (1.24) | 0.54 |
| Grade ≥3 complications | 54 (20.1%) | 5 (20.0%) | 1.00 | 11 (22.0%) | 5 (20.0%) | 1.00 |
| Acute rejection | 23 (8.6%) | 4 (16.0%) | 0.39 | 6 (12.0%) | 4 (16.0%) | 0.90 |
| Hospital stay (days) | 15.9 (17.4) | 15.1 (9.4) | 0.81 | 14.3 (6.6) | 15.1 (9.4) | 0.69 |
| ITU stay (days) | 4.2 (3.2) | 3.9 (4.0) | 0.73 | 4.2 (2.6) | 3.9 (4.0) | 0.74 |
| Biliary complications | 49 (18.2%) | 6 (24.0%) | 0.66 | 9 (18.0%) | 6 (24.0%) | 0.76 |
| Anastomotic | ||||||
| Overall | 40 (14.9%) | 4 (16.0%) | 1.00 | 6 (12.0%) | 4 (16.0%) | 0.90 |
| Symptomatic | 31 (11.5%) | 4 (16.0%) | 0.73 | 5 (10.0%) | 4 (16.0%) | 0.71 |
| Post-transplant cholangiopathy | ||||||
| Overall | 13 (4.8%) | 2 (8.0%) | 0.83 | 4 (8.0%) | 2 (8.0%) | 1.00 |
| Symptomatic | 6 (2.2%) | 0 (0%) | 0.99 | 2 (4%) | 0 (0%) | 0.80 |
Data are expressed as mean (standard deviation) or number (percentage). *p-value referring to Mann-Whitney, Chi-square or Fisher’s test, as appropriate. Abbreviations: SCS, static cold storage; HOPE, hypothermic oxygenated machine perfusion; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LT, liver transplantation.